Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature. The widely held view is that these antiangiogenic therapies should destroy the tumor vasculature, thereby depriving the tumor of oxygen and nutrients. Here, I review emerging evidence supporting an alternative hypothesis—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. Drugs that induce vascular normalization can alleviate hypoxia and increase the efficacy of conventional therapies if both are carefully scheduled. A better understanding of the molecular and cellular underpinnings of vascular normalization may ultimately lead to more effective therapies not only for cancer but also for diseases with abnormal vasculature, as well as regenerative medicine, in which the goal is to create and maintain a functionally normal vasculature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the aberrant vasculature also restricts the access of recruited immune cells and anticancer therapeutics to tumors, resulting in reduced outcomes of cancer treatments.[ 18 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [18]
In the citing paper
“Recently, research groups such as Jain, et al., have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [24]
In the citing paper
“Because the tumor vasculature is immature (12) and lacks myogenic and autonomic regulation (5)”
In the citing paper
“Conversely, increased glycolytic rate and low perfusion/oxygenation contribute to intratumoral hypoxia and acidosis, which is alleviated with enhanced perfusion (12).”
In the citing paper
“A rationale for combining anti-VEGF therapy with chemotherapy is that anti-VEGF therapy caused tumor vasculature to normalize resulting in increased drug delivery to tumors [123].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [123]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citation
Research works printed but not linked: 12
- D. J. Hicklin L. M. Ellis J. Clin. Oncol. in press.
- J. Ma et al., Cancer Res.61, 5491 (2001).
- R. K. Jain, in Clinical Oncology, M. Abeloff et al., Eds. (Elsevier, New York, ed. 3, 2004), pp. 153–172.
- R. K. Jain, Clin. Cancer Res.5, 1605 (1999).
- C. G. Lee et al., Cancer Res.60, 5565 (2000).
- A. Kadambi et al., Cancer Res.61, 2404 (2001).
- M. Relf et al., Cancer Res.57, 963 (1997).
- Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, R. K. Jain, Nature416, 279 (2002).
- P. Perrotte et al., Clin. Cancer Res.5, 257 (1999).
- P. M. Gullino, in Biomedical Thermology, M. Gautherie, E. Albert, Eds. (A. R. Liss, New York, 1982), pp. 1–20.
- L. Flintoft, Nature Rev. Cancer4, 754 (2004).
- G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, R. K. Jain, Cancer Res.59, 3776 (1999).
Cited by
Items 601–700 of 1,035
Different angiogenic phenotypes in primary and secondary glioblastomas
Karcher, S., Steiner, H., Ahmadi, R., Zoubaa, S., Vasvari, G., Bauer, H., Unterberg, A., & Herold‐Mende, C. (2006) · International Journal of Cancer · doi:10.1002/ijc.21648 · Cited by 145
Kossatz, S., Ludwig, R., Dähring, H., Ettelt, V., Rimkus, G., Marciello, M., Salas, G., Patel, V., Teran, F. J., & Hilger, I. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1417-0 · Cited by 144
“Interestingly, it has been shown that less aggressive therapeutic approaches can be beneficial for tumor regression compared to more radical approaches leading to hypoxic areas by destroying tumor vasculature (37).”
BackgroundAdvanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma
Kalpathy–Cramer, J., Gerstner, E. R., Emblem, K. E., Andronesi, O. C., & Rosen, B. R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0383 · Cited by 158
“Current thinking centers around the "vascular normalization hypothesis" (26, 27), in which anti-”
BackgroundIntravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer
Nobis, M., McGhee, E. J., Morton, J. P., Schwarz, J. P., Karim, S. A., Quinn, J., Edward, M., Campbell, A. D., McGarry, L. C., Evans, T. R. J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4545 · Cited by 143
Imaging Heterogeneity in Lung Cancer: Techniques, Applications, and Challenges
Bashir, U., Siddique, M. M., McLean, E., Goh, V., & Cook, G. (2016) · American Journal of Roentgenology · doi:10.2214/ajr.15.15864 · Cited by 148
Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer
Liang, P., Ballou, B. T., Lv, X., Si, W., Bruchez, M. P., Huang, W., & Dong, X. (2021) · Advanced Materials · doi:10.1002/adma.202005155 · Cited by 161
Sacchi, A., Gasparri, A., Gallo-Stampino, C., Toma, S., Curnis, F., & Corti, A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1147 · Cited by 144
Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients
van Meir, H., Nout, R. A., Welters, M. J. P., Loof, N. M., de Kam, M. L., van Ham, J. J., Samuels, S., Kenter, G. G., Cohen, A. F., Melief, C. J. M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1267095 · Cited by 143
Metzger, G. J. (2007) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.023 · Cited by 144
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
Fack, F., Espedal, H., Keunen, O., Golebiewska, A., Obad, N., Harter, P. N., Mittelbronn, M. G. A., Bähr, O., Weyerbrock, A., Stuhr, L. E. B., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1352-5 · Cited by 156
“Preclinical models of other cancers suggest that antiangiogenic therapy may cause a temporary vascular normalization leading to increased blood perfusion and improved oxygen delivery [25].”
BackgroundRecent Advances in the Biology of Heavy-Ion Cancer Therapy
Hamada, N., Imaoka, T., Masunaga, S., Ogata, T., Okayasu, R., Takahashi, A., Kato, T. A., Kobayashi, Y., Ohnishi, T., Ono, K., et al. (2010) · Journal of Radiation Research · doi:10.1269/jrr.09137 · Cited by 154
Targeted Therapies for Ovarian Cancer
Grunewald, T., & Ledermann, J. A. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.12.001 · Cited by 154
Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy
Mistry, I. N., Thomas, M., Calder, E. D. D., Conway, S. J., & Hammond, E. M. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.03.024 · Cited by 154
Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow
Gillies, R. J., Brown, J. S., Anderson, A. R. A., & Gatenby, R. A. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0030-7 · Cited by 144
Vascular normalisation as the stepping stone into tumour microenvironment transformation
Magnussen, A. L., & Mills, I. G. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01330-z · Cited by 146
Essential Roles of EphB Receptors and EphrinB Ligands in Endothelial Cell Function and Angiogenesis
(2012) · Advances in Cancer Research · doi:10.1016/b978-0-12-386503-8.00002-8 · Cited by 141
“$w aterm ark-text $w aterm ark-text $w aterm ark-text tumor vasculature (Jain, 2005).”
BackgroundFalcón, B. L., Chintharlapalli, S. R., Uhlik, M. T., & Pytowski, B. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.001 · Cited by 149
Angiogenesis in atherosclerosis: gathering evidence beyond speculation
Moulton, K. S. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000245261.71129.f0 · Cited by 155
Mechanisms of Disease: angiogenesis and the management of breast cancer
Banerjee, S. N., Dowsett, M., Ashworth, A., & Martin, L. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0905 · Cited by 156
“Another possibility is that antiangiogenic agents transiently normalize the tumor vasculature allowing more efficient oxygen and chemotherapy delivery”
BackgroundRole of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
Rapisarda, A., & Melillo, G. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.03.002 · Cited by 141
“Evidence has been provided supporting both a vascular regression, which is presumably associated with increased intra-tumor hypoxia (Kerbel and Folkman, 2002) and a so-called “normalization” of tumor vasculature, with a consequent decrease in interstitial pressure and better delivery of chemotherapy (Jain, 2005).”
BackgroundGordon-Weeks, A. N., Lim, S. Y., Yuzhalin, A. E., Jones, K. I., Markelc, B., Kim, K. J., Buzzelli, J. N., Fokas, E., Cao, Y., Smart, S., et al. (2017) · Hepatology · doi:10.1002/hep.29088 · Cited by 153
“These morphological findings are consistent with changes sometimes termed vascular normalization, whereby vessels are remodeled resulting in improved oxygen delivery.((29)) In keeping with these observations, tumors from GAL-F2-treated mice displayed a significant reduction in hypoxia compared to those from control an…”
ResultKudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., Izumi, N., Yamasaki, T., Nojiri, S., Hino, K., et al. (2022) · Liver Cancer · doi:10.1159/000522547 · Cited by 141
Calcinotto, A., Grioni, M., Jachetti, E., Curnis, F., Mondino, A., Parmiani, G., Corti, A., & Bellone, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101877 · Cited by 140
“Lymphocyte infiltration in tumors can also be favored by the use of antiangiogenic compounds, such as anti-VEGFAbs (7, 45–47) that are also able to inhibit the formation of new blood vessels and promote vascular normalization (48).”
BackgroundMechanisms of resistance to anti-angiogenesis therapies
Giuliano, S., & Pagès, G. (2013) · Biochimie · doi:10.1016/j.biochi.2013.03.002 · Cited by 158
“This may explain the efficacy of combination of BVZ and chemotherapy [16] (Fig.”
BackgroundVEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
Duda, D. G., Batchelor, T. T., Willett, C. G., & Jain, R. K. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.04.001 · Cited by 156
“Finally, based on preclinical observations, it has been suggested that anti-VEGF agents can ‘normalize’ tumor vasculature [9,44] (Figure 1).”
BackgroundSelf-citationThe Tumor Microenvironment in Non–Small-Cell Lung Cancer
Graves, E. E., Maity, A., & Le, Q.-T. (2010) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.01.003 · Cited by 138
Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy
Wang, W., Cheng, Y., Yu, P., Wang, H., Zhang, Y., Xu, H., Ye, Q., Yuan, A., Hu, Y., & Wu, J. (2019) · Nature Communications · doi:10.1038/s41467-019-09389-2 · Cited by 139
Redundant angiogenic signaling and tumor drug resistance
Gacche, R. N., & Assaraf, Y. G. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.002 · Cited by 144
Stylianopoulos, T., Soteriou, K., Fukumura, D., & Jain, R. K. (2013) · Annals of Biomedical Engineering · doi:10.1007/s10439-012-0630-4 · Cited by 139
Self-citationAgarwala, S. S., Keilholz, U., Gilles, E. M., Bedikian, A. Y., Wu, J., Kay, R., Stein, C. A., Itri, L. M., Suciu, S., & Eggermont, A. M. M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.016 · Cited by 144
Powathil, G., Gordon, K. E., Hill, L., & Chaplain, M. A. J. (2012) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2012.05.015 · Cited by 135
The Warburg Effect in Endothelial Cells and its Potential as an Anti-angiogenic Target in Cancer
Fitzgerald, G., Soro-Arnáiz, I., & Bock, K. D. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00100 · Cited by 145
“Cell fates within the growing sprout are transient and ECs continuously overtake each other, alternating at the tip cell position (Bentley et al., 2009; Jakobsson et al., 2010; Arima et al., 2011).”
BackgroundMicroscopic imaging techniques for drug discovery
Bullen, A. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2446 · Cited by 140
“These studies have been useful in identifying novel mechanisms of action, suggesting that these therapies may actually work by normalizing tumour vasculature rather than by destroying i”
BackgroundDuda, D. G., Jain, R. K., & Willett, C. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3985 · Cited by 138
Self-citationLewin, M., Fartoux, L., Vignaud, A., Arrivé, L., Menu, Y., & Rosmorduc, O. (2010) · European Radiology · doi:10.1007/s00330-010-1914-4 · Cited by 138
“Indeed, in addition to their destructive action on tumor microvessels, antiangiogenics drugs have been suggested to improve the quality of the remaining vessels in terms of basement membrane thickness and pericyte coverage resulting in decreased vascular permeability and interstitial fluid pressure [29].”
BackgroundFyles, A., Milosevic, M., Pintilie, M., Syed, A., Levin, W., Manchul, L., & Hill, R. P. (2006) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2006.07.014 · Cited by 145
Altaner, Č. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.023 · Cited by 138
“Directing drugs to cancer cells in the tumor mass is often limited by unequal vascularization and necrotic regions [73].”
BackgroundHuang, Y., Chen, Y., Zhou, S., Liang, C., Wang, J., Pei, Y., Xu, M., Feng, J., Jiang, T., Liang, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14425-7 · Cited by 145
Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments
Sun, T., & Jiang, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114773 · Cited by 137
Patterson, D. M., & Rustin, G. J. S. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.03.014 · Cited by 146
Lee, S. M., Woll, P. J., Rudd, R., Ferry, D. R., O'Brien, M. E. R., Middleton, G., Spiro, S. G., James, L. E., Ali, K., Jitlal, M., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp200 · Cited by 136
Direct and indirect regulation of the tumor immune microenvironment by VEGF
Zhang, Y., & Brekken, R. A. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ru0222-082r · Cited by 156
Probing the Microenvironment of Mammary Tumors Using Multiphoton Microscopy
Sidani, M., Wyckoff, J. B., Xue, C., Segall, J. E., & Condeelis, J. S. (2006) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-006-9021-5 · Cited by 141
Hlushchuk, R., Riesterer, O., Baum, O., Wood, J. M., Gruber, G., Pruschy, M. N., & Djonov, V. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.071131 · Cited by 153
Bello, C. L., Sherman, L. J., Zhou, J., Verkh, L., Smeraglia, J., Mount, J., & Klamerus, K. J. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200603000-00015 · Cited by 136
Hagendoorn, J., Tong, R., Fukumura, D., Lin, Q., Lobo, J., Padera, T. P., Xu, L., Kucherlapati, R., & Jain, R. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2655 · Cited by 136
“Because optimal scheduling of antiangiogenic agents can increase the effectiveness of conventional cytotoxic therapy by reversing abnormalities in tumor blood vasculature (4), understanding the functional changes in blood and lymphatic vasculature may have broad implications for treatment of early cancer stages.”
BackgroundSelf-citationTargeting the ATF4 pathway in cancer therapy
Singleton, D. C., & Harris, A. L. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.728207 · Cited by 135
“These features arise as a result of inefficient perfusion by the dysfunctional tumour microvasculature to meet the metabolic demands of proliferating cancer cells [2].”
BackgroundTumor Angiogenesis and Vascular Patterning: A Mathematical Model
Travasso, R. D. M., Poiré, E. C., Castro, M., Rodríguez-Manzaneque, J. C., & Hernández-Machado, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019989 · Cited by 156
“Recently, the concept of normalizationof tumor vasculature has been proposed [8].”
BackgroundImpact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide
Zhou, Q., Guo, P., & Gallo, J. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4544 · Cited by 135
von Schwarzenberg, J., Czernin, J. G., Cloughesy, T. F., Ellingson, B. M., Pope, W. B., Geist, C. L., Dahlbom, M. L., Silverman, D. H. S., Satyamurthy, N., Phelps, M. E., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.092387 · Cited by 135
“Furthermore, it reduces vasogenic edema, allowing for a reduction or discontinuation of corticosteroids (27).”
BackgroundTargeting Tumor Microenvironment by Small-Molecule Inhibitors
Zhong, S., Jeong, J.-H., Chen, Z., Chen, Z., & Luo, J.-L. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.10.001 · Cited by 134
“Therefore, some therapeutic strategies are designed to normalize tumor vasculature, which can alleviate hypoxia in tumor and increase the efficacy of therapies [127].”
BackgroundMitsos, S., Katsanos, K. H., Koletsis, E. N., Kagadis, G. C., Anastasiou, N., Διαμαντόπουλος, Α., Karnabatidis, D., & Dougenis, D. (2011) · Angiogenesis · doi:10.1007/s10456-011-9240-2 · Cited by 144
“As seen in preclinical models, VEGF has been shown to facilitate survival of existing vessels, contribute to vascular abnormalities that may impede effective delivery of antitumor compounds, and stimulate new vessel growth [28–32].”
BackgroundClinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors
Iv, M., Telischak, N., Feng, D., Holdsworth, S. J., Yeom, K. W., & Daldrup-Link, H. E. (2015) · Nanomedicine · doi:10.2217/nnm.14.203 · Cited by 134
Endoglin-Targeted Cancer Therapy
Seon, B. K., Haba, A., Matsuno, F., Takahashi, N., Tsujie, M., She, X., Harada, N., Uneda, S., Tsujie, T., Toi, H., et al. (2010) · Current Drug Delivery · doi:10.2174/156720111793663570 · Cited by 134
“One possible mechanism is that anti-ENG mAb normalizes tumor vasculature in vivo which will lead to enhancement of the antitumor efficacy of cyclophosphamide and other drugs [72, 73].”
BackgroundNovel Therapies for Metastatic Castrate-Resistant Prostate Cancer
Dayyani, F., Gallick, G. E., Logothetis, C. J., & Corn, P. G. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr362 · Cited by 141
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal
Haemmerle, M., Bottsford-Miller, J., Pradeep, S., Taylor, M. L., Choi, H.-J., Hansen, J. M., Dalton, H. J., Stone, R. L., Cho, M. S., Nick, A. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85086 · Cited by 134
Role of hypoxia in the tumor microenvironment and targeted therapy
Chen, G., Wu, K., Li, H., Xia, D., & He, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961637 · Cited by 346
Reardon, D. A., Desjardins, A., Peters, K. B., Gururangan, S., Sampson, J. H., McLendon, R. E., Herndon, J. E., Bulusu, A., Threatt, S., Friedman, A. H., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0722-2 · Cited by 139
Magar, A. G., Morya, V. K., Kwak, M. K., Oh, J. U., & Noh, K.-C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063313 · Cited by 341
“This HIF-1 α -mediated vascular remodeling results in a leaky vasculature within the TME, increasing plasma protein permeability, and promoting tumor growth and propagation [60].”
BackgroundLeung, C. S., Yeung, T.-L., Yip, K.-P., Wong, K.-K., Ho, S. Y., Mangala, L. S., Sood, A. K., Lopez-Berestein, G., Sheng, J., Wong, S. T. C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci95200 · Cited by 132
“Blood vessels in tumor tissue are usually poorly organized and leaky, which impairs drug delivery (17).”
BackgroundCrosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications
Li, J., & Harris, A. L. (2009) · Frontiers in bioscience · doi:10.2741/3438 · Cited by 141
“To some extent, blockade of VEGF may also normalise the remaining vessels in tumour to help deliver nutrients and oxygen (116).”
Jain, R. K., & Carmeliet, P. (2012) · Cell · doi:10.1016/j.cell.2012.05.025 · Cited by 151
“, and Jain, R.K. (2011). Normalization of the vasculature for treatment of cancer and other diseases.”
Self-citationBevacizumab for the Treatment of Recurrent Glioblastoma
Chamberlain, M. C. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7232 · Cited by 153
The Essential Role of Fibroblasts in Esophageal Squamous Cell Carcinoma–Induced Angiogenesis
Noma, K., Smalley, K. S. M., Lioni, M., Naomoto, Y., Tanaka, N., El‐Deiry, W. S., King, A. J., Nakagawa, H., & Herlyn, M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.061 · Cited by 148
Molecular targeting of glioblastoma: Drug discovery and therapies
Bai, R.-Y., Staedtke, V., & Riggins, G. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.011 · Cited by 158
Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
Sun, W. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-63 · Cited by 129
“In normal tissues, there is a balance between proangiogenic and antiangiogenic factors [2].”
BackgroundInfluentialXiao, X., Chen, X., Guan, X., Wu, H., Qin, W., & Luo, B. (2016) · British Journal of Radiology · doi:10.1259/bjr.20160546 · Cited by 131
Defenders and Challengers of Endothelial Barrier Function
Rahimi, N. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01847 · Cited by 152
Angiogenesis in cancer: molecular mechanisms, clinical impact
Eichhorn, M., Kleespies, A., Angele, M. K., Jauch, K. ‐., & Bruns, C. J. (2007) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-007-0150-0 · Cited by 153
“mechanism is normalization of tumor microvessels by antiangiogenic therapy, first proposed by Jain [39, 40] in 2001.”
Shaked, Y., Emmenegger, U., Francia, G., Chen, L., Lee, C. R., Man, S., Paraghamian, A., Ben-David, Y., & Kerbel, R. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0765 · Cited by 131
Mucci, L. A., Powolny, A. A., Giovannucci, E. L., Liao, Z., Kenfield, S. A., Shen, R. Z., Stampfer, M. J., & Clinton, S. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8876 · Cited by 130
“Our data on vessel morphology and architecture further support the importance of angiogenesis in prostate cancer progression and the hypothesis that disease progression is marked by a rapid formation of neovasculature in tumors that are of smaller size and more poorly formed.(14,15) The leaky and disordered function o…”
BackgroundResultA Systems Approach for Tumor Pharmacokinetics
Thurber, G. M., & Weissleder, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024696 · Cited by 130
“Therapies such as bevacizumab and other antiangiogenic treatments ‘normalize’ tumor blood vessels by reducing permeability, increasing pericytes coverage, and restoring pressure gradients [53].”
BackgroundDll4-Notch signaling as a therapeutic target in tumor angiogenesis
Kuhnert, F., Kirshner, J. R., & Thurston, G. (2011) · Vascular Cell · doi:10.1186/2045-824x-3-20 · Cited by 134
“Preclinical studies have suggested a model in which the normalization of tumor vessels achieved by anti-VEGF therapy allows for more efficient delivery of oxygen and drug into the tumor [73].”
Bell‐McGuinn, K. M., Garfall, A. L., Bogyo, M. S., Hanahan, D., & Joyce, J. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0602 · Cited by 135
“antiangiogenic agents, in part due to improved drug delivery (44).”
BackgroundTherapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery
Chen, Y., Liu, X., Yuan, H., Yang, Z., von Roemeling, C. A., Qie, Y., Zhao, H., Wang, Y., Jiang, W., & Kim, B. Y. S. (2019) · Advanced Science · doi:10.1002/advs.201802070 · Cited by 130
The biological implications of Yin Yang 1 in the hallmarks of cancer
Meliala, I. T. S., Hosea, R., Kasim, V., & Wu, S. (2020) · Theranostics · doi:10.7150/thno.43481 · Cited by 135
“This results in a fluctuating and unstable oxygen supply to tumor tissues [84].”
BackgroundAugustin, R. C., Delgoffe, G. M., & Najjar, Y. G. (2020) · Cancers · doi:10.3390/cancers12123802 · Cited by 129
“Further disruption of already dysfunctional vessels has been shown to increase intratumoral hypoxia; a vicious cycle that upregulates HIF-1α, exacerbating many of the resistant mechanisms already described [46].”
BackgroundSanga, S., Frieboes, H. B., Zheng, X., Gatenby, R. A., Bearer, E. L., & Vittorio Cristini, C. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.05.043 · Cited by 131
“This result could be achieved by pruning immature and inefficient blood vessels, leading to a more normal vasculature of vessels reduced in diameter, density, and permeability (Jain, 1990, 2001, 2005).”
BackgroundVisualization of Hypoxia in Microscopic Tumors by Immunofluorescent Microscopy
Li, X.-F., Carlin, S., Urano, M., Russell, J., Ling, C. C., & O'Donoghue, J. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4353 · Cited by 130
Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia
von Degenfeld, G., Banfi, A., Springer, M. L., Wagner, R. A., Jacobi, J., Ozawa, C. R., Merchant, M. J., Cooke, J. P., & Blau, H. M. (2006) · The FASEB Journal · doi:10.1096/fj.06-6568fje · Cited by 130
“Therapeutic VEGF inhibition prunes such abnormalities, transiently resulting in a vasculature that is smaller in diameter and closer to normal, resulting in increased tumor blood supply and oxygenation in a seemingly paradoxical manner (34).”
Overview of anti-angiogenic agents in development for ovarian cancer
Burger, R. A. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.11.035 · Cited by 150
“Anti-angiogenic therapy is designed to restore the balance between proangiogenic and anti-angiogenic factors and thereby flip the angiogenic switch back to the off position [5,7].”
BackgroundInfluentialTumor Angiogenesis and Anti-angiogenic Therapy
Kubota, Y. (2012) · The Keio Journal of Medicine · doi:10.2302/kjm.61.47 · Cited by 128
Zhao, Y., Kim, H., Nguyen, V.-N., Jang, S., Jang, W. J., & Yoon, J. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215560 · Cited by 137
A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Strome, S. E., Sausville, E. A., & Mann, D. L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1084 · Cited by 147
“Interestingly, this effect may be short-lived, because tumor blood vessels eventually collapse after prolonged VEGF blockade, possibly leading to development of VEGF resistance [ 29 ].”
BackgroundAvraham, H. K., Jiang, S., Fu, Y., Nakshatri, H., Ovadia, H., & Avraham, S. (2014) · The Journal of Pathology · doi:10.1002/path.4304 · Cited by 128
“Resistance to anti-angiogenic therapy that targets VEGF is attributed to the inherent heterogeneity of genetically unstable tumour cells, the presence of redundant angiogenic factors, and the recruitment of haematopoietic cells and inflammatory cells into the tumour mass [21,22].”
BackgroundFokas, E., Im, J. H., Hill, S. A., Yameen, S., Stratford, M. R. L., Beech, J. S., Hackl, W., Maira, S.-M., Bernhard, E. J., McKenna, W. G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2263 · Cited by 145
“Blockade of the VEGF pathway normalized blood vessel and improved oxygenation, providing a window for combination with radiotherapy (7).”
BackgroundInfluentialMathematical modeling of brain tumors: effects of radiotherapy and chemotherapy
Powathil, G., Kohandel, M., Sivaloganathan, S., Oza, A. M., & Milosevic, M. (2007) · Physics in Medicine and Biology · doi:10.1088/0031-9155/52/11/023 · Cited by 127
“The tumor vascular network is very abnormal, characterized by interstitial hypertension, hypoxia and acidosis (Jain 2005).”
BackgroundDzobo, K., Senthebane, D. A., Ganz, C., Thomford, N. E., Wonkam, A., & Dandara, C. (2020) · Cells · doi:10.3390/cells9081896 · Cited by 127
Endothelial Regulation of Drug Transport in a 3D Vascularized Tumor Model
Haase, K., Offeddu, G. S., Gillrie, M. R., & Kamm, R. D. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202002444 · Cited by 127
The current knowledge concerning solid cancer and therapy
Najafi, M., Majidpoor, J., Toolee, H., & Mortezaee, K. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22900 · Cited by 143
Pegylated liposomal doxorubicin in ovarian cancer.
Green, A. E., & Rose, P. G. (2006) · PubMed Central · Cited by 128
Sun, D., Liu, Y., Yu, Q., Qin, X., Yang, L., Zhou, Y., Chen, L., & Liu, J. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.007 · Cited by 127
“and Ru(2-(4-11-mercaptoamide-N-phenyl)-imidazo [4,5f] [1,10] phenanthroline) (phenanthroline)2(PF6)2$2H2O (Ru-MUA) [17] were according to methods in the supporting information.”
BackgroundMethodMaking Microvascular Networks Work: Angiogenesis, Remodeling, and Pruning
Pries, A. R., & Secomb, T. W. (2014) · Physiology · doi:10.1152/physiol.00012.2014 · Cited by 148
“These findings relate to anti-angiogenic therapy and the concept of “vascular normalization” with the aim of improving the susceptibility of the tumor to chemotherapy or radiation (30, 38).”
BackgroundInvestigating the EPR effect of nanomedicines in human renal tumors via ex vivo perfusion strategy
Ding, Y., Xu, Y., Yang, W., Niu, P., Li, X., Chen, Y., Li, Z., Liu, Y., An, Y., Liu, Y., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100970 · Cited by 127
Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting
Lee, J., Choi, M., & Song, I. (2023) · Pharmaceuticals · doi:10.3390/ph16060802 · Cited by 160
“Circulating PEGylated liposomes (PLs) of a size of 100–200 nm are mainly deposited in tumor cells that a have large, leaky spaces in pericytes but not in normal tissue with tight capillary junctions, in what is known as the enhanced permeation and retention (EPR) effect [29,30].”
BackgroundIn vitro three-dimensional tumor microenvironment models for anticancer drug discovery
Smalley, K. S., Lioni, M., Noma, K., Haass, N. K., & Herlyn, M. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.1.1 · Cited by 126
“Ultimately, this leads to the co-option of neighboring host vessels as well as the recruitment of circulating endothelial cell precursors leading to the establishment of new microvessels (reviewed in [35] ).”
BackgroundHeist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., Temel, J. S., Shaw, A. T., Pennell, N. A., Neal, J. W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424024112 · Cited by 126
Self-citationMazzocca, A., Fransvea, E., Lavezzari, G., Antonaci, S., & Giannelli, G. (2009) · Hepatology · doi:10.1002/hep.23118 · Cited by 127
Efficient Treg depletion induces T‐cell infiltration and rejection of large tumors
Li, X., Kostareli, E., Suffner, J., Garbi, N., & Hämmerling, G. J. (2010) · European Journal of Immunology · doi:10.1002/eji.201041093 · Cited by 126
Yang, J., Li, W., Luo, L., Jiang, M., Zhu, C., Qin, B., Yin, H., Yuan, X., Yin, X., Zhang, J., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.08.004 · Cited by 127
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Science
- Published
- 2005-01-07
- Volume
- 307
- Issue
- 5706
- Pages
- 58-62
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2006202974
- Cited by
- 5,527
- References
- 56
- Citations by year
- 2026: 245 · 2025: 212 · 2024: 202 · 2023: 220 · 2022: 236 · 2021: 279 · 2020: 245 · 2019: 236 · 2018: 219 · 2017: 236 · 2016: 252 · 2015: 292 · 2014: 307 · 2013: 361 · 2012: 350
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- tumor vasculature normalization, anti-angiogenic therapy, tumor hypoxia, tumor oxygenation, drug delivery to tumors, combination cancer therapy, regenerative medicine, vascular function
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Cell Hypoxia, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.